Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Study of Resection and GammaTile® Followed by Concurrent External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ) and Adjuvant TMZ Versus Standard of Care in Newly Diagnosed Glioblastoma (GBM)

NCT07195591 is registered in ClinicalTrials.gov with GT Medical Technologies, Inc. as lead sponsor.

NCT NCT07195591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07195591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Study of Resection and GammaTile® Followed by Concurrent External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ) and Adjuvant TMZ Versus Standard of Care in Newly Diagnosed Glioblastoma (GBM)
Lead sponsor
GT Medical Technologies, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
December 10, 2025
Completion date
December 31, 2031
Enrollment
766 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma